BRCA1 and Hereditary breast and ovarian cancer syndrome: Accurately characterizing BRCA1/2 mutational status, including BRCA1/2 somatic and germline mutations, can guide treatment for patients with these gene alterations and help assess the risk of developing hereditary breast and ovarian cancer (HBOC).